What is the market's earnings forecast for Revolution Medicines next quarter?

What guidance did Revolution Medicines's management provide for the next earnings period?

What is Revolution Medicines's latest dividend and current dividend yield?

What does Revolution Medicines do and what are its main business segments?

What is the revenue and EPS growth rate for Revolution Medicines year over year?

What were the key takeaways from Revolution Medicines's earnings call?

What factors drove the changes in Revolution Medicines's revenue and profit?

What is Revolution Medicines's gross profit margin?

- **Pancreatic Cancer Breakthrough:** Daraxonrasib Phase III data show 13.1-15.6 months OS in second-line PDAC,优于化疗的6-7个月。FDA vouchers可能加速审批。
- **First-Line Potential:** First-line daraxonrasib单药和化疗组合分别达到47%和55%的ORR，耐受性良好。
- **Lung Cancer Expansion:** Elironrasib在晚期NSCLC中实现42% ORR；daraxonrasib + pembrolizumab组合进入注册试验。
- **Financial Strength:** $1.93B现金支持临床和商业化扩张，2025年净亏损指引为$1.03-1.09B。
- **Commercial Momentum:** 美国和欧洲区域负责人就位，加速全球上市准备。

**【CEO Summary Section】**
- Revolution Medicines is advancing its RAS-targeted therapies for pancreatic, lung, and colorectal cancers. Key assets include daraxonrasib (RASON inhibitor) and zoldonrasib (G12D-selective inhibitor).
- Daraxonrasib received FDA Breakthrough Therapy, Orphan Drug, and Commissioner’s National Priority Vouchers for pancreatic cancer, highlighting its potential to address unmet needs.
- Phase III trials (RASolute 302, 303, 304) are progressing for daraxonrasib in second-line, first-line, and adjuvant pancreatic cancer settings. First-line data show 47% ORR (monotherapy) and 55% ORR (combination with chemo).
- Expansion into non-small cell lung cancer (NSCLC) includes daraxonrasib in Phase III vs docetaxel and elironrasib (G12C inhibitor) showing 42% ORR in late-line NSCLC.
- Global commercialization efforts are scaling with regional leaders appointed in the U.S. and Europe.

**【CMO Clinical Updates】**
- **Pancreatic Cancer:**
 - RASolute 302 Phase III nears completion; second-line daraxonrasib monotherapy shows 8+ months PFS and 13.1-15.6 months OS vs 6-7 months for chemo.
 - First-line trials (monotherapy and combo with chemo) demonstrate 47-55% ORR and durable safety profiles.
 - Adjuvant trial (RASolute 304) randomizes post-chemo patients to 2 years of daraxonrasib vs observation.
- **Lung Cancer:**
 - Daraxonrasib + pembrolizumab/chemo Phase II shows encouraging antitumor activity in first-line NSCLC.
 - Elironrasib (G12C) monotherapy in late-line NSCLC achieves 42% ORR and 6.2-month PFS.
- **Colorectal Cancer:**
 - Exploring combination strategies with RASON inhibitors and other mechanisms.

**【CFO Financial Commentary】**
- Q3 2025 cash balance: $1.93 billion (includes $250M royalty tranche).
- R&D expenses: $262.5M (vs $151.8M YoY), driven by clinical trials (daraxonrasib Phase III) and manufacturing.
- G&A expenses: $52.8M (vs $24.0M YoY), due to headcount expansion and commercial prep.
- Full-year 2025 GAAP net loss guidance: $1.03-1.09B, including $115-130M stock-based comp.

**【Q&A Highlights】**
- **Voucher Impact:** Potential 1-2 month NDA review acceleration; company prepared for rapid launch.
- **Adjuvant Trial Design:** 4+ months chemo eligibility ensures standard-of-care alignment; randomization to daraxonrasib vs observation tests adjuvant benefit.
- **Commercial Readiness:** Manufacturing and field teams scaling; U.S. and EU launch plans advancing.
- **Resistance Mechanisms:** Exploring RASON doublets (e.g., zoldonrasib + daraxonrasib) to overcome resistance in PDAC and NSCLC.
- **Colorectal Strategy:** Combination therapies prioritized due to biological complexity.

Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call Transcript

Collaboration

RVMD

RVMD fundamentals

You can ask Aime